Effect of electroacupuncture on the expression of Nav1.1 in rat after acute cerebral ischemia.
OBJECTIVE
To observe the expression of Nav1.1 and the effect of electroacupuncture therapy (ET) on it after acute cerebral ischemia.


METHODS
Focal acute cerebral ischemic model was established by occluding right middle cerebral artery. One hundred and forty-five male adult Sprague-Dawley rats were randomly divided into four groups: sham operation group, middle cerebral artery occlusion (MCAO) group, ET group and riluzole group. Double immunofluorescence and real-time PCR were used to observe Nav1.1 expression, and TTC staining was used to detect infarct volume at 6 hours, 1 day, 2 days, 3 days and 7 days after ischemia.


RESULTS
The expression of Nav1.1 in sham operation group had no change. After ischemia, the expression of Nav1.1 was up-regulated evidently at 6 hours compared with sham operation group, down-regulated at 1 day and up-regulated again from 2 to 7 days after ischemia; the expression at 7 days was lower than that at 6 hours. In ET group and riluzole group, Nav1.1 expression were down-regulated compared with that in MCAO group after ischemia, the infarct volume was smaller than that in MCAO group at the same time point, and the difference is significant (p<0.05); however, the difference between ET group and riluzole group is not significant (p>0.05).


CONCLUSIONS
ET and riluzole could regulate the expression of Nav1.1 after ischemia, decrease the infarction volume and reduce cerebral ischemic injury. One of the important mechanisms for ET's cerebral protective function may be that it could regulate the expression of Nav1.1 after ischemia.
Ren
Li
L
Department of Neurology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Fang
Yan nan
Yn
Zhang
Ai wu
Aw
Li
Xiang liang
Xl
Wang
Xiao juan
Xj
Yin
Zhao
Z
Miao
Jia yin
Jy
D000704:Analysis of Variance; D000818:Animals; D001921:Brain / Q000378:metabolism*; D015671:Electroacupuncture; D005455:Fluorescent Antibody Technique; D020244:Infarction, Middle Cerebral Artery / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D008297:Male; D062550:NAV1.1 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019782:Riluzole / Q000494:pharmacology / Q000627:therapeutic use; D015222:Sodium Channels / Q000235:genetics / Q000378:metabolism*
D062550:NAV1.1 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; C568250:Scn1a protein, rat; D015222:Sodium Channels; D019782:Riluzole